Skip to main content

$0.010 (0%)

High

$0.01

Low

$0.01

Trades

20

Turnover

$16,459

Volume

1,641,703
30 June 2023 at 4:10pm
Register to track PAB and receive email alerts.
Subject
PAB Ann: Patrys Receives R&D Tax Incentive Refund

PAB Ann: PAT-DX1 engineering update

PAB Ann: Ceasing to be a substantial holder from MQG

PAB Ann: Ceasing to be a substantial holder

PAB Ann: Section 708A Cleansing Statement

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Change of Director's Interest Notices x2

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Rights Issue Results and Shortfall Notification

PAB Ann: Notification regarding unquoted securities - PAB

PAB Ann: Change of Director's Interest Notice

PAB Ann: Notification regarding unquoted securities - PAB

PAB Ann: Notification regarding unquoted securities - PAB

PAB Ann: Becoming a substantial holder from MQG

PAB Ann: Dispatch of Offer Letter to Eligible Shareholders

PAB Ann: Letter to Ineligible Shareholders

PAB Ann: Letter to Eligible Shareholders - Entitlement Offer

PAB Ann: Rights Issue Offer Document

PAB Ann: Notice under Section 708AA(2)(F) - Entitlement Offer

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Section 708A Cleansing Statement

PAB Ann: Results of Annual General Meeting

PAB Ann: Chairman's Address and CEO Presentation to 2021 AGM

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Letter to Optionholders - Entitlement Offer

PAB Ann: Notice under Section 708AA(2)(F) - Entitlement Offer

PAB Ann: Investor Presentation

PAB Ann: Proposed issue of securities - PAB

PAB Ann: $7.8M Capital Raising

PAB Ann: Change of Company Secretary

PAB Ann: Trading Halt

PAB Ann: Appendix 4C - Quarterly - 30 September 2021

PAB Ann: Patrys proof of concept ADC significantly increases survival

PAB Ann: Notice of Annual General Meeting/Proxy Form

PAB Ann: Company Overview Presentation - September 2021

PAB Ann: Patrys to Present at Lifesciences Webinar

PAB Ann: PAT-DX3 proof of concept as potential ADC targeting antibody

PAB Ann: Change of Director's Interest Notice

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Section 708A Cleansing Statement

PAB Ann: Appendix 4G and Corporate Governance Statement

PAB Ann: Appendix 4E and 2021 Annual Report

PAB Ann: Market Update - PAT-DX1 Clinical Trial Preparation

PAB Ann: Appendix 4C - Quarterly - 30 June 2021

PAB Ann: Change in substantial holding

PAB Ann: PAT-DX1 Improves Survival in Model of Pancreatic Cancer

PAB Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier

PAB Ann: Application for quotation of securities - PAB

PAB Ann: Section 708A Cleansing Statement

PAB Ann: Response to ASX Query

Register to track PAB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX